Vendor, San Diego, CA
Novomedix LLC
UEI XQYMHKGDMU75, CAGE 4C2X1
2 awards and $2,977,013 obligated between April 12, 2024 and September 30, 2025, 100% under full and open competition, against 31.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $2,977,013 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00051Definitive Contract, September 15, 2025, Full and Open Competition After Exclusion of Sources, 16 offers | NIH NCINational Institutes of Health | SBIR Phase II - Enhanced Overall Survival in High-Risk Pediatric Solid Tumors Using a Novel Oral Small MoleculeNAICS 541715, PSC AN12 | $2,977,013 |
| 75N91022C00001Definitive Contract, April 12, 2024, Full and Open Competition After Exclusion of Sources, 47 offers | NIH NCINational Institutes of Health | SBIR Concept Award to Novomedix- Novel Small Molecules for the Treatment of RhabdomyosarcomaNAICS 541715, PSC AN12 | $0 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 3 across 2 awards